All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

teneligliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
dipeptidyl aminopeptidase-IV inhibitors	4895	760937-92-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: teneligliptin teneligliptin hydrobromide teneligliptin hydrobromide hydrate tenelia	A long-acting, orally bioavailable, pyrrolidine-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Teneligliptin may also reduce plasma triglyceride levels through a sustained increase in GLP-1 levels. Molecular weight: 426.58 Formula: C22H30N6OS CLOGP: 2.49 LIPINSKI: 0 HAC: 7 HDO: 1 TPSA: 56.64 ALOGS: -2.48 ROTB: 4

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 29, 2012	PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pemphigoid	62.31	37.54	14	515	7330	63481163

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	51.26	30.60	22	1029	27433	34928447
Cardiac failure	35.47	30.60	26	1025	91222	34864658
Pemphigoid	34.29	30.60	12	1039	8654	34947226
Interstitial lung disease	30.91	30.60	21	1030	65261	34890619

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	76.35	30.13	31	1736	45645	79696976
Pemphigoid	70.25	30.13	22	1745	15293	79727328
Renal impairment	40.36	30.13	31	1736	157752	79584869
Interstitial lung disease	39.97	30.13	27	1740	112573	79630048
Cardiac failure	36.52	30.13	29	1738	154813	79587808
Hypoglycaemia	32.83	30.13	23	1744	101571	79641050
Hepatic function abnormal	31.98	30.13	20	1747	73087	79669534

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10BH08	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Dipeptidyl peptidase 4 (DPP-4) inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.33	Basic
pKa2	4.33	Basic
pKa3	2.09	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Dipeptidyl peptidase 4	Enzyme	P27487	DPP4_HUMAN	INHIBITOR	IC50	9.43		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Dipeptidyl peptidase 8	Enzyme	Q6V1X1	DPP8_HUMAN		IC50	6.59		SCIENTIFIC LITERATURE
Dipeptidyl peptidase 9	Enzyme	Q86TI2	DPP9_HUMAN		IC50	6.27		SCIENTIFIC LITERATURE
Dipeptidyl peptidase 4	Enzyme		DPP4_RAT		IC50	9.54		CHEMBL

External reference:

ID	Source
28ZHI4CF9C	UNII
D08616	KEGG_DRUG
1572583-29-9	SECONDARY_CAS_RN
C2981308	UMLSCUI
CHEBI:136042	CHEBI
M51	PDB_CHEM_ID
CHEMBL2147777	ChEMBL_ID
11949652	PUBCHEM_CID
DB11950	DRUGBANK_ID
8994	INN_ID
C579035	MESH_SUPPLEMENTAL_RECORD_UI
9906	IUPHAR_LIGAND_ID
1172794002	SNOMEDCT_US
1172797009	SNOMEDCT_US
1172926000	SNOMEDCT_US

Pharmaceutical products:

None